Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioma 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × TIC10 compound × 90 days × Clear all
NCT05580562 2026-04-16

ACTION

Jazz Pharmaceuticals

Phase 3 Recruiting
510 enrolled
CNS

Glioma

NCT02392572 2026-04-14

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
120 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡